Researchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.
Additional Covid-19 vaccine booster shots are not needed for the general population, leading scientists including two departing senior U.S. Food and Drug Administration officials and several from the World Health Organization (WHO) said in an article published in a medical journal on Sept. 13.
The body of real-world evidence around Covid-19 continues to build, and a study released Aug. 26 in The Lancet points to concerning long-term effects for hospital survivors at the one-year mark.
AstraZeneca’s Covid-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on July 28, after worries over side effects.
Eli Lilly’s investigational diabetes drug tirzepatide is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. In other positive clinical results presented at the American Diabetes Association’s 81st Scientific Sessions meeting, Novo Nordisk data demonstrated an investigational 2mg dose of injectable Ozempic (semaglutide) generated statistically significant and superior reductions in A1C compared to a 1mg dose of Ozempic.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the Covid-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.
Bristol Myers Squibb announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70th Annual Scientific Session with simultaneous publication in The Lancet.
Prime Minister Narendra Modi sounded the alarm over the rapid spread of Covid-19 through India’s vast countryside on May 14, as 4,000 people died from the virus for the third straight day and total infections crossed 24 million.
The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford Covid-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77 percent efficacy in children over 12 months of follow-up.